Entero Healthcare Solutions Limited will hold its 8th Annual General Meeting (AGM) on August 19, 2026, at 12:30 P.M. (IST) through Video Conferencing (VC) or Other Audio Visual Means (OAVM). The company has dispatched physical letters to shareholders who have not registered email addresses with the company, its Registrar and Transfer Agent (RTA), or Depository Participants, providing a weblink to access the Annual Report for FY26. This move ensures compliance with SEBI Listing Regulations while encouraging a green initiative by reducing paper usage.

The intimation was issued pursuant to Regulations 30 and 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sanu Kapoor, Vice President- Group General Counsel, Company Secretary & Compliance Officer, confirmed that the information is also available on the company’s website. The letter serves as a notice for shareholders without registered emails to access critical governance documents digitally.

Key Details

Shareholders can access the complete Annual Report for FY26 at www.enterohealthcare.com . The exact path provided is: https://www.enterohealthcare.com/investor/annual_report/annual-report.php . This digital access is mandated under Regulation 36(1)(b) of the SEBI Listing Regulations for members who have not registered their email addresses.

The cut-off date for identifying shareholders without registered emails was July 17, 2026. The company requests all shareholders to update their email addresses through their depository participants or by communicating directly with the company or its RTA, MUFG Intime India Private Limited (formerly Link Intime India Private Limited). This update facilitates the receipt of important information and documents electronically, aligning with the company’s green initiative.

For any queries or service requests, shareholders are directed to use the helpdesk portal at https://web.in.mpms.mufg.com/helpdesk/Service_Request.html or call +91 810 811 6767. The company emphasizes that all shareholder communications should be routed through these official channels to ensure timely resolution.

Entero Healthcare Solutions Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the Bombay Stock Exchange and National Stock Exchange of India. The filing, dated July 27, 2026, discloses a consolidated turnover of ₹65,91,21,21,789.48 and a net worth of ₹16,88,61,04,602.23 as of March 31, 2026. The report provides a comprehensive overview of the company’s operational footprint, which includes 48 subsidiaries and 137 offices nationwide, while detailing its adherence to regulatory standards under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company operates exclusively within India, serving 21 states and union territories through a business-to-business model that caters to retail pharmacies, hospitals, nursing homes, and clinics. Entero Healthcare does not engage in export activities, meaning its entire turnover is derived from domestic distribution and marketing of pharmaceuticals, surgical items, and allied healthcare products. The reporting boundary encompasses the consolidated financial statements of the listed entity and all its subsidiaries.

Organizational Structure and Subsidiaries

As of the end of FY26, Entero Healthcare manages a network of 48 subsidiaries. During the reporting period, the company underwent several structural changes. Chethana Pharma Distributors Private Limited and CPD Pharma Private Limited, wholly-owned subsidiaries of Rada Medisolutions Private Limited, were merged via the fast-track route effective April 15, 2025. Conversely, three non-operational entities—Zennx Software Private Limited, Quomed Lifesciences Private Limited, and Rimedio Pharma Private Limited—were struck off on May 01, 2025, June 02, 2025, and June 05, 2025, respectively. Additionally, the company divested its 100% equity stake in Suprabhat Pharmaceuticals Private Limited by selling it back to its erstwhile promoters, removing it from the subsidiary list.

Employee Demographics and Welfare

The workforce comprises 4,943 employees and 27 workers. Among employees, 4,671 are permanent, with males constituting 73.71% and females 26.29% of this segment. The remaining 272 employees are non-permanent. Worker demographics show 27 permanent workers, with females representing 62.96% of this small cohort. The company reported no differently abled employees or workers during the period.

Turnover rates for permanent employees stood at 35.94% in FY26, a slight decrease from 38.27% in FY25. For permanent workers, the turnover rate was 20.00%, compared to 0.00% in the previous year. Women representation remains significant at the leadership level, with two women on the eight-member Board of Directors (25.00%) and one woman among the two Key Managerial Personnel (50.00%).

Environmental Impact and Resource Usage

Entero Healthcare disclosed total energy consumption from non-renewable sources at 2,25,67,219.85 Megajoules in FY26, up from 1,90,83,596.95 Megajoules in FY25. This increase is reflected in the energy intensity per rupee of turnover, which adjusted for Purchasing Power Parity (PPP), rose from 0.0077 to 0.0069 Megajoules/Rs. The company consumed 11,160 kilolitres of water, sourced entirely from third parties, with an intensity of 0.0000034 kilolitres/Rs. adjusted for PPP.

Greenhouse gas emissions saw a mixed trend. Scope 1 emissions decreased significantly to 744.18 metric tonnes of CO2 equivalent from 1,270.56 in FY25. However, Scope 2 emissions increased to 4,282.00 metric tonnes from 4,113.21. Total waste generated rose to 870.00 metric tonnes, primarily consisting of cartons and food waste, with no recycling or recovery operations reported. All waste was disposed of via landfilling.

Governance and Compliance

The company reported no fines, penalties, or legal actions related to bribery, corruption, or conflict of interest during FY26. One employee-related complaint was received via the SCORES portal but was resolved internally and closed. The Board of Directors oversees the implementation of business responsibility policies, with Managing Director Prabhat Agrawal identified as the highest authority responsible. The company maintains policies on attendance, medical claims, travel, conflict of interest, and grievance redressal, though these do not currently extend to value chain partners.